Plasma Androstenedione Concentration Can Discriminate Frail versus Non-Frail Men with Prostate Cancer under Androgen Deprivation Therapy.

Autor: Mafla-España MA; Nursing Department, University of Valencia, 46010 Valencia, Spain.; Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain., Torregrosa MD; Medical Oncology Department, Doctor Peset University Hospital, 46017 Valencia, Spain., Beamud-Cortés M; Urology Department, Doctor Peset University Hospital, 46017 Valencia, Spain., Bermell-Marco L; Urology Department, Doctor Peset University Hospital, 46017 Valencia, Spain., Rubio-Briones J; Urology Clinic, Hospital VITHAS 9 de Octubre, 46015 Valencia, Spain., Cauli O; Nursing Department, University of Valencia, 46010 Valencia, Spain.; Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain.; Chair of Healthy, Active and Participative Ageing, University of Valencia, 46010 Valencia, Spain.
Jazyk: angličtina
Zdroj: Biomolecules [Biomolecules] 2023 Nov 13; Vol. 13 (11). Date of Electronic Publication: 2023 Nov 13.
DOI: 10.3390/biom13111642
Abstrakt: Background: Androgen deprivation therapy (ADT) is a mainstay of prostate cancer in both adjuvant and palliative settings. Since androgens are crucial for functional status and psychological functions, we evaluated whether blood testosterone, androstenedione, or DHEA concentrations were associated with functional status and psychological alterations in patients with localised (PCa) or metastatic prostate cancer (mPCa) receiving ADT with analogues of luteinising hormone-releasing hormone (LHRH).
Methods: The five Fried criteria were considered to identify frailty syndrome. In addition, complementary evaluations were carried out to measure other variables of interest. Sleep quality was assessed using the Athens Insomnia Scale, cognitive functions were assessed using the Mini-Mental State Examination, and symptoms of depression were measured using the Yesavage Geriatric Depression Scale. Logistic regression analysis was performed to determine if the androgens level could be related to frailty syndrome, sleep impairment, depressive symptoms, and cognitive functions.
Results: The results of the multivariate analyses show that high concentrations of androstenedione were significantly associated with frailty syndrome in both groups ( p = 0.018; odds ratio = 4.66, 95% confidence interval [1.30-16.6]). There were significant relationships between frailty syndrome and the systemic concentration of androstenedione ( p = 0.01), but not the concentration of testosterone ( p = 0.60) or DHEA ( p = 0.42). In addition, the results of the non-parametric tests show significant results between a decreased gait speed in the two groups (metastatic and localised) and the concentration of androstenedione ( p = 0.015). High androstenedione levels were associated with a slow walking speed in the mCaP group ( p = 0.016), while high testosterone levels were associated with a better walking speed in the localised CaP group ( p = 0.03). For the concentration of androstenedione in plasma, the area under the curve was 0.72, with a 95% CI of 0.55-0.88 with acceptable values, and with a cut-off point of 4.51 pg/mL, a sensitivity of 82.9%, and specificity of 53.8%. No relationships between the concentration of androgens in plasma and sleep quality, cognitive functions, or symptoms of depression suggest that the changes were specific to frailty syndrome.
Conclusions: Further research into the role of androstenedione should be evaluated in follow-up studies in order to recommend its use as a suitable biomarker of frailty syndrome in prostate cancer patients.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje